What sector does Kilitch Drugs India Ltd belong to?

Kilitch Drugs India Ltd operates in the Healthcare sector, specifically the Pharmaceuticals industry, and is listed on the NSE.

What is the current share price of KILITCH?

As of the latest available quote, KILITCH traded at ₹185.97. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of KILITCH?

Kilitch Drugs India Ltd has a price-to-earnings (P/E) ratio of about 21.13. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of KILITCH?

The market capitalisation of Kilitch Drugs India Ltd is approximately ₹650 Cr.

Is Kilitch Drugs India Ltd profitable?

For its latest reported financial year, Kilitch Drugs India Ltd recorded a net profit margin of about 12.77%.

Does KILITCH pay a dividend?

Kilitch Drugs India Ltd does not currently show a dividend yield in our data.

What is the return on equity (ROE) of KILITCH?

Kilitch Drugs India Ltd has a return on equity (ROE) of about 10.60%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of KILITCH?

Over the past 52 weeks, KILITCH has traded between a low of ₹117.25 and a high of ₹219.50.

Kilitch Drugs India Ltd

KILITCH NSE Healthcare Pharmaceuticals

₹185.97

+0.51%

Delayed · cached 15 min

Fair value analysis

KILITCH

Kilitch Drugs India Ltd

₹185.03

Close used for this calculation

₹215.42Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

48/100

Profitability21/25

Returns8/25

Balance Sheet9/25

Efficiency10/25

Growth17/25

Average

Quality radar

Consensus fair value

₹215.42

Below FV

▲ +16.4% against the close used

Model range ₹91.32 – ₹388.66

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹91.32Fair value₹215.42Bull₹388.66

FairClose

52-week traded range

52W low ₹124.4552W high ₹205.52

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading below the consensus fair value

Kilitch Drugs India Ltd closed at ₹185.03, 14.1% below the consensus fair value of ₹215.42 drawn from 9 valuation models.

Financial DNA score 48/100 — Average. P/E of 21.6x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

₹171.30

-7.4%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=9%, r=10%, tg=3%, n=10yr

Graham Number

₹124.18

-32.9%

√(22.5 × EPS × BVPS)

EPS=8.63, BVPS=79.41 · outside Graham range (P/E 21.6, P/B 2.3) — asset-light, treat as a rough floor

Graham Formula

₹388.66

+110.1%

EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate

g=20%, FD=7%

P/E Fair Value

₹308.09

+66.5%

EPS × 35.7x (sector P/E)

EPS=8.63, Sector P/E=35.7x

Peter Lynch (PEG)

₹215.75

+16.6%

EPS × Growth% (PEG = 1 is fair)

EPS=8.63, g=25%

EV/EBITDA

₹184.75

-0.2%

(EBITDA × 18x − Net Debt) ÷ Shares

EBITDA=410M

Book Value (P/B)

₹91.32

-50.6%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=79.41, ROE=10.6%, g=6%, r=10%

Reverse DCF

₹185.03

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 8.1% | Historical: 25%

Margin of Safety

₹186.04

+0.5%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=248.06, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer